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Fleshing Out Filaggrin Phenotypes
Alan D. Irvine1,2
The association of filaggrin null alleles with eczema has been replicated in sev-
eral European populations. Three large, well-conducted studies confirm this 
association and offer insights into the phenotypic nature of eczema associat-
ed with these alleles. Early data suggest that FLG-associated eczema may be 
more persistent, more likely to have palmar hyperlinearity, and more likely to 
be associated with asthma. These initial hints will require further confirmation 
in cohort studies.
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Earlier this year, two recurrent null 
alleles in filaggrin (FLG) were observed 
to confer substantial risk of atopic der-
matitis (AD; henceforth called ecze-
ma, according to the World Allergy 
Organization nosology (Johansson et al., 
2004)) and of asthma occurring in the 
context of eczema (Palmer et al., 2006). 
Within a short time these two null 
alleles in FLG (R501X and 2282del4) 
have become the most widely and inde-
pendently replicated and most strongly 
associated genetic factor conferring 
susceptibility to eczema in European 
populations to date, with odds ratios of 
between 3.73 and 7.1 reported in the 
larger cohorts (Marenholz et al., 2006; 
Ruether et al., 2006). In this issue of the 
Journal of Investigative Dermatology, 
three additional replication studies are 
reported (Barker et al., 2007; Stemmler 
et al., 2007; Weidinger et al., 2007). 
Each of these studies reports strong 
association between eczema and FLG 
null alleles, and each allows further 
exploration of the genetic contribution 
of these common recurrent null alleles 
to the pathogenesis of eczema. A sum-
mary of the populations studied to date 
and relevant findings is presented in 
Table 1. Significantly, all studies have 
shown strong replication of associa-
tion with eczema, and no negative or 
equivocal study in Europeans, in whom 
these mutations are prevalent, has been 
reported. The position of FLG as a major 
gene in AD is further reinforced by the 
striking finding that these two common 
recurrent mutations have a penetrance 
of 42% in the German Multicenter 
Allergy Study and that the population 
attributable risk factor (the proportion 
of eczema that is directly attributable to 
these two recurrent null alleles at popu-
lation level assuming a causal asso-
ciation) for eczema in this cohort was 
11% (Marenholz et al., 2006). These 
calculations of the total cumulative 
effect of FLG null alleles in eczema are 
likely to be an underestimate, as sever-
al additional recurrent FLG null alleles 
are present in European populations 
at lower levels with intra-European, 
regionally distinct allele frequencies (A. 
Sandilands, W.H.I. McLean, and A.D. 
Irvine, unpublished data).
Given such a strong gene effect, and 
given that these same alleles cause the 
distinct phenotype of ichthyosis vulgar-
is in a semidominant inheritance pat-
tern (Smith et al., 2006), it is reasonable 
to ask whether the phenotypic charac-
teristics of eczema related to FLG null 
alleles can in any way be dissected out 
from the broad and inclusive concept 
of eczema suggested by current guide-
lines. Subcategorization of eczema 
based on elevated circulating specific 
IgE levels (into atopic and nonatopic, or 
extrinsic and intrinsic forms) has been 
widely suggested, but it has failed to 
increase our predictive ability in terms 
of phenotype or course of disease (Flohr 
et al., 2004). In particular, elevated IgE 
levels are less relevant in community-
based studies than in hospital-based 
studies (Flohr et al., 2004). Could the 
presence or absence of FLG null alleles 
help define sub-phenotypes and predict 
the course of eczema? Examination of 
the early data allows a degree of cau-
tious interpretation as to the precise 
contribution of FLG null alleles to ecze-
ma phenotypes and to the consider-
ation of possible genotype–phenotype 
correlates. Within cohorts that have 
been ascertained through attendance 
of people with eczema at dermatology 
clinics, some recurrent themes emerge. 
Two large series of adult patients with 
AD presenting to hospital clinics show 
a high frequency of FLG null car-
rier rates in adults who have persistent 
AD with onset within the first 2 years 
(29.7% in a German cohort (Weidinger 
et al., 2007), and 42% in an English 
cohort (Barker et al., 2007)). These 
observations suggest that individuals 
with eczema who carry FLG null alleles 
could be more likely to have early 
onset and persistent disease, although 
controls with late-onset eczema and 
cohort studies are needed for further 
proof of such a notion. In well-charac-
terized eczema cohorts from Munich, 
these alleles predispose to elevated 
IgE as a secondary trait (Weidinger et 
al., 2006; Weidinger et al., 2007). This 
predisposition was also seen in the 
extended Genetic Studies in Nuclear 
Families with Atopic Dermatitis cohort 
(Marenholz et al., 2006) and in relation 
to “extrinsic” AD (AD plus sensitization 
determined by positive skin-prick test-
ing or specific IgE elevation) (Weidinger 
et al., 2007). These findings may reflect 
the more severe spectrum of disease 
seen in hospital studies, where elevated 
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These early data hint at 
possible discriminating 
features of eczema 
associated with FLG 
null alleles.
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Table 1. Summary of genetic studies of association of FLG null alleles with eczema and related phenotypes
Cohort/ethnicity Number of subjects and 
characteristics of cohort 
Phenotype examined P value
(combined 
genotype)
Odds ratio % patients with 
one or more FLG 
null alleles
Irish1
(Sandilands et al., 2006)
10 large multiplex families with 
ichthyosis vulgaris and AD
AD and
ichthyosis vulgaris
LOD 3.96 NA NA
Irish2
(Palmer et al., 2006)
52 children, early onset, severe AD AD 3 × 10–17 13.4 (6.2–27.5) 56
English3
(Barker et al., 2007)
163 early onset, persistent AD AD 1.7 × 10–53 7.7 (5.3–10.9) 42
German4
(Ruether et al., 2006)
272 children with AD AD 2.01 × 10–8 7.1 (3.41–14.78) 35
German5
(R501X only typed)f
(Ruether et al., 2006)
338 trios AD 0.0016 3.59 (1.75–6.58) 14.2 (R501X only)
Scottish
(Dundee BREATHE)
(Palmer et al., 2006)
279 (children recruited through 
asthma clinics)
AD + asthma 4.8 × 10–11 3.3 (2.0–5.6) 23
German6
(Weidinger et al., 2006)
476 trios (recruited though hospital-
based dermatology clinics)
AD 5.1 × 10–8 Not calculated 22.75
Allergic sensitization 2.3 × 10–7 Not calculated
Total IgE 9.8 × 10–8 Not calculated
Asthma 0.0003 Not calculated
Palmar hyperlinearity 5.9 × 10–6 Not calculated
Extrinsic AD 9.3 × 10–8 Not calculated
German7
(Stemmler et al., 2007)
378 patients with AD (210 onset 
<2 years)
Onset <2 years
All AD
7.6 × 10–7 Not calculated 21.3
German8
(Weidinger et al., 2007)
274 adults AD
IgE
Asthma
Rhinitis
Intrinsic eczema
4.9 × 10–5
0.010
2.5 × 10–6
2.4 × 10–5
No association
3.53 (1.92–6.48)
Not calculated
Not calculated
Not calculated
No association
21.1
Early onset, 29.7
German9
(GENUFAD cohort)
(Marenholz et al., 2006)
490 nuclear families
903 cases with moderate to severe 
eczema
Eczema 1.9 × 10–9 Not calculated 18.6
Eczema + asthma 0.00042 Not calculated
Eczema + allergic rhinitis 2.5 × 10–5 Not calculated
Eczema + increased IgE 1.9 × 10–9 Not calculated
German10
(MAS cohort)
(Marenholz et al., 2006)
871 children,
population-based, longitudinal study 
up to 10 years
189 eczema
118 asthma
Eczema (n = 155) 3.5 × 10–5 3.73 (1.98–7.02) 16.7
Nonatopic eczema
(n = 63)
0.00065 3.94 (1.7–8.9) Not recorded
Eczema + asthma
(n = 40)
5.4 × 10–8 6.21 (2.6–14.8) 25
Eczema + rhinitis
(n = 44)
1.5 × 10–5 4.75 (2.0–11.6) 20
Danish (COPSAC)11
(Palmer et al., 2006)
142 (children born to asthmatic 
mothers)
AD <0.0001 2.8 (1.7–4.5) 17.5
Genetic analysis models: 1linkage analysis; 2case-control χ2; 3case-control χ2; 4case-control χ2; 5case-control χ2; 6transmission disequilibrium test; 
7transmission disequilibrium test; 8case-control χ2; 9case-control χ2; 10family-based association; kcase-control χ2; 11case-control χ2. AD, atopic dermatitis; 
BREATHE; COPSAC, Copenhagen Prospective Study on Atopy in Children; GENUFAD, Genetic Studies in Nuclear Families with Atopic Dermatitis; MAS, 
Multicenter Allergy Study; NA, not applicable.
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IgE is more commonly found (Flohr et 
al., 2004), and it is interesting that in a 
birth-cohort study, FLG-null status was 
also strongly associated with nonatopic 
eczema (Marenholz et al., 2006). Thus, 
elevated circulating IgE may be primar-
ily an epiphenomenon that is a proxy 
for severity in eczema and is therefore 
more represented in hospital-ascer-
tained series (Flohr et al., 2004).
Although the relationship between 
FLG null alleles and asthma remains to 
be fully understood, in eczema cohorts 
where asthma status has been ascer-
tained there is a consistent additional 
association with asthma as a secondary 
trait (Marenholz et al., 2006; Weidinger 
et al., 2006; Weidinger et al., 2007). 
The more informative cohorts in this 
regard are those ascertained through a 
diagnosis of asthma, and population-
based cohorts. In the Dundee BREATHE 
cohort, the association of FLG with 
asthma was entirely limited to the 
subgroup with a coincident history of 
eczema, with no association between 
FLG alleles and asthma in the absence 
of eczema (Palmer et al., 2006). 
Similarly, in the German Multicenter 
Allergy Study cohort, FLG alleles had 
no association with asthma or aller-
gic sensitization in the absence of 
prior eczema (Marenholz et al., 2006). 
Importantly, this study also observed 
an additional risk of asthma in patients 
homozygous for FLG null alleles and 
calculated a striking population attrib-
utable risk factor of 20.6% for FLG null 
alleles for the phenotype eczema plus 
asthma (Marenholz et al., 2006). These 
data suggest a sequence of phenotypic 
manifestations rather than individual 
susceptibilities to each of these manifes-
tations of atopy and also allow specula-
tion that early control of eczema may 
have an impact on future development 
of asthma, a concept that has already 
begun to be explored in studies such as 
the Early Treatment of the Atopic Child 
study (Warner, 2001).
Taken together, these early data 
hint at possible discriminating fea-
tures of eczema associated with FLG 
null alleles: that the eczema is more 
strongly associated with asthma, has 
associated hyperlinearity of the palms, 
and is more likely to be persistent into 
adulthood. An additional association 
with elevated IgE is also possible but 
not yet clear. This tentative analysis will 
doubtless be tempered as additional 
data become available, but it suggests 
a starting point to explore genotype–
phenotype correlations. It should also 
be noted that although these carefully 
phenotyped cohorts where participants 
have been recruited through a diag-
nosis of eczema are very informative, 
they are unable to fully answer the 
question of what (if anything) is differ-
ent about FLG-related eczema versus 
non-FLG-related eczema, nor can they 
determine the relative risk of FLG null 
alleles to asthma, atopy, and rhinitis (if 
any) per se. Large longitudinal or cross-
sectional population-based cohorts that 
have been typed for all FLG variants will 
facilitate the dissection of these pheno-
typic characteristics and will enable 
researchers to compare and contrast 
FLG phenotypes versus others to test 
these speculations. Given the xerotic 
phenotype of ichthyosis vulgaris (Smith 
et al., 2006), which is seen in many 
eczema sufferers, future studies observ-
ing additional physical parameters of 
skin barrier function, such as the degree 
of skin hydration, the rate of transepi-
dermal water loss, and susceptibility 
to skin irritation, may help to test the 
hypothesis of a “dry or defective bar-
rier” type of FLG-related eczema. The 
pharmacogenetic significance of filag-
grin status in predicting possible treat-
ment responses to interventions such 
as emollients, soap substitution, water 
softening, or pharmacological interven-
tion, and whether such interventions 
alter the disease trajectory, will also be 
worth examining.
To date, filaggrin has not been shown 
to be a susceptibility factor for eczema 
in non-European populations. There 
are a few possible explanations for this, 
including the fact that the currently 
known recurrent mutations either are 
not present or are present at very low 
levels in many non-European popula-
tions (Palmer et al., 2006). Also, except 
in Japan, few research groups have 
established data sets of non-European 
eczema patients for genetic analysis. 
The technical difficulties of sequenc-
ing filaggrin may mean that it will take 
some time to determine the role of FLG 
mutations in populations outside of 
Europe. The incomplete penetrance of 
these alleles also merits further atten-
tion and is presumably explained by 
both genetic and environmental modi-
fiers. Possible genetic modifiers of 
FLG null-allele penetrance include 
SPINK5 (Walley et al., 2001) and 
SCCE (Vasilopoulos et al., 2004), both 
of which have been associated with 
eczema and both of which are plau-
sibly involved in controlling filaggrin 
processing. Much has been learned in 
a short time about the role of FLG sta-
tus in eczema. Much more needs to be 
understood about its function before 
this knowledge can be translated direct-
ly into patient benefit.
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Pseudoxanthoma Elasticum-Like 
Phenotypes: More Diseases than One
Jouni Uitto1 and Qiujie Jiang1
The classic pseudoxanthoma elasticum (PXE) phenotype derives from muta-
tions in ABCC6. PXE-like phenotypes have been observed in a number of dis-
orders, with no evidence of mutations in ABCC6. Vanakker et al. report PXE-
like skin findings in patients with mutations in GGCX critical for γ-carboxyl-
ation of gla-proteins. This report expands the clinical spectrum of PXE-like 
conditions and also provides potential insights into the ectopic mineraliza-
tion process.
Journal of Investigative Dermatology (2007) 127, 507–510. doi:10.1038/sj.jid.5700635
Pseudoxanthoma elasticum (PXE), a 
mendelian autosomal recessive disor-
der, is characterized by ectopic mineral-
ization of connective tissues in a variety 
of organs, including the skin, the eyes, 
and the cardiovascular system, with 
considerable morbidity and mortal-
ity (Neldner, 1988). PXE is now known 
to result from mutations in the ABCC6 
gene (Miksch et al., 2005). This gene 
encodes multidrug resistance-associ-
ated protein 6 (MRP6), a putative trans-
membrane transporter, expressed pri-
marily in the liver, to a lesser extent in 
proximal tubules of kidneys, and at very 
low levels, if at all, in tissues affected in 
PXE. Adding to the complexity of this 
disorder are the observations that there 
is considerable both inter- and intrafa-
milial heterogeneity, the diagnosis is 
often delayed because of late onset of 
manifestations, and a number of envi-
ronmental and lifestyle variables appear 
to modulate the progression and even-
tual outcome of the disease. Finally, 
the disease has been suggested to be 
more severe in women, and the female–
male ratio of affected individuals has 
been reported to be approximately 2:1 
(Neldner, 1988). It is conceivable, there-
fore, that a number of both genetic and 
environmental factors contribute to the 
phenotypic variability of PXE.
Two hypotheses have been advanced 
to explain the consequences of ABCC6 
mutations in PXE at the tissue level: the 
“metabolic disease hypothesis” and the 
“PXE cell hypothesis.” The metabolic 
disease hypothesis suggests that PXE is 
a metabolic disorder, and that, in the 
absence of MRP6 transport activity in 
the liver, the plasma levels of critical 
metabolic compounds are altered (Uitto 
et al., 2001). Change in the plasma 
homeostasis would then promote, by 
currently unknown mechanisms, miner-
alization of the peripheral target tissues. 
In this context, it should be noted that 
MRP6 is a putative basolateral transport-
er in hepatocytes, and the direction of 
the transport in a physiologic situation 
is probably from the intracellular milieu 
of hepatocytes to plasma in circulation. 
Thus, one could argue that the main 
function of such metabolites in normal 
homeostasis is to prevent ectopic min-
eralization, and that if the MRP6 trans-
porter is not functional, there is deple-
tion of metabolites in the circulation, 
resulting in aberrant mineralization in 
the extracellular milieu (Figure 1).
The PXE cell hypothesis postulates 
that inactivation of ABCC6 results in 
abnormalities in the resident cells in 
tissues affected in PXE, such as der-
mal fibroblasts in the skin and arte-
rial smooth muscle cells in the vascular 
connective tissues. In support of this 
hypothesis, a number of activities have 
been shown to be altered in fibroblasts 
cultured from the skin of patients with 
PXE. For example, the cells harboring 
the mutations have been suggested to 
display abnormalities in cell–cell and 
cell–matrix adhesion properties, in their 
proliferative capacity, and in the rate 
of synthesis of connective tissue com-
ponents, such as elastin, collagen, and 
proteoglycans (Boraldi et al., 2003). 
These cells have also been suggested to 
suffer from mild chronic oxidative stress 
and to demonstrate increased degrada-
tive potential as reflected by elevated 
matrix metalloproteinase 2 expres-
sion (Quaglino et al., 2005; Pasquali-
Ronchetti et al., 2006).
In support of the suggestion that com-
promised MRP6 activity in resident cells 
in affected tissues may alter the activity 
of such cells is the observation that low 
levels of the protein and mRNA have 
been detected by immunofluorescence 
staining, by highly sensitive RNase 
protection assays, and by multi-round, 
nested RT-PCR approaches (Beck et al., 
2003). It is clear, however, that the level 
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